Australia Pen Needles Market Size, Share, and COVID-19 Impact Analysis, By Product (Standard Pen Needles and Safety Pen Needles), By Therapy (Insulin, Glucagon-like-peptide-1, and Growth Hormone), and Australia Pen Needles Market Insights, Industry Trend, Forecasts to 2035

Australia Pen Needles Market Insights Forecasts to 2035

• The Australia Pen Needles Market Size Was Estimated at USD 101.4 Million in 2024
• The Market Size is Expected to Grow at a CAGR of Around 12.54% from 2025 to 2035
• The Australia Pen Needles Market Size is Expected to Reach USD 371.9 Million by 2035

According to a research report published by Spherical Insights & Consulting, the Australia pen needles market size is anticipated to reach USD 371.9 million by 2035, growing at a CAGR of 12.54% from 2025 to 2035. The pen needles market in Australia is driven by the rising incidence of diabetes, increased use of insulin pens, an ageing population, increased obesity, better government reimbursement, and a need for safer, thinner, and more pleasant injectable solutions

Market Overview

The Australia pen needles market refers to the production, distribution, and sale of disposable needles designed for use with insulin pens and other injectable drug delivery devices. The needles come in different sizes, which include multiple lengths and gauge options to improve patient safety and comfort. The primary uses of the applications involve diabetes treatment through insulin delivery and the administration of GLP-1 therapies and other injectable drugs in Australian hospitals and clinics, and home care environments.

The National Diabetes Services Scheme in Australia provides free or subsidised insulin pen needles, which eligible patients can use to obtain 1200 needles every 180 days. The Pharmaceutical Benefits Scheme (PBS) reduces insulin prices, which state governments use to pay for co-payments, thus enabling diabetes patients who use pen-based injection systems to access their medication at lower costs.

The Australia pen needle market has seen recent changes through the introduction of ultra-thin low-pain pen needles, which suppliers now make more widely accessible and through their smart insulin delivery systems, which enable precise dosing measurement. The local distributors for the company will start to sell additional items. The company will achieve future growth through digital connectivity features and better comfort designs, and the increasing use of GLP-1 and biologic injections, which will enhance patient treatment commitment.

Report Coverage

This research report categorizes the market for the Australia pen needles market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Australia pen needles market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Australia pen needles market.

Driving Factors

The pen needles market in Australia is driven by the increasing number of people developing diabetes, as more patients start using insulin pens, and the number of elderly people increases. Patients now experience better comfort and treatment compliance because people understand self-administration better, and they want injections that provide a safer and less painful experience, and because technological advancements created ultra-thin and smart pen needles. The market expansion receives support from government programs, which include the NDSS and PBS, because these initiatives make pen needles more affordable and accessible to people throughout the country.

Restraining Factors

The pen needles market in Australia is mostly constrained by the advanced and smart needle designs, which create high expenses, and certain patient groups lack product knowledge. The market depends on insulin pen adoption, and there exists competition from alternative drug delivery systems like insulin pumps.

Market Segmentation

The Australia pen needles market share is classified into product and therapy.

• The standard pen needles segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The Australia pen needles market is segmented by product into standard pen needles, and safety pen needles. Among these, the standard pen needles segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. They are the go-to option for managing diabetes on a daily basis because of their extensive availability, affordable price, and compatibility with the majority of insulin pens. Compared to safety pen needles, their dependability, simplicity, and convenience of use encourage more acceptance, which results in the highest revenue share and steady market growth.

• The insulin segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. 

The Australia pen needles market is segmented by therapy into insulin, glucagon-like-peptide-1, and growth hormone. Among these, the insulin segment dominated the share in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. This is because insulin is still the most popular injectable treatment for both type 1 and type 2 diabetes. The greatest revenue share and steady growth are driven by high diabetes prevalence, rising insulin pen use, and frequent daily doses as opposed to GLP-1 or growth hormone therapy.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Australia pen needles market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• BD (Becton, Dickinson and Company) Australia Pty Ltd
• Owen Mumford Australia Pty Ltd
• Sanofi-Aventis Australia Pty Ltd
• Novo Nordisk Pharmaceuticals Pty Ltd
• Eli Lilly Australia Pty Ltd
• F. Hoffmann-La Roche Ltd
• Medtronic Australasia Pty Ltd
• Smith Medical Australasia Pty Ltd
• Terumo Australia Pty Ltd
• Dexcom Australia Pty Ltd
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the Australia, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Australia pen needles market based on the below-mentioned segments:

Australia Pen Needles Market, By Product

• Standard Pen Needles
• Safety Pen Needles

Australia Pen Needles Market, By Therapy

• Insulin
• Glucagon-like-peptide-1
• Growth Hormone